journal
MENU ▼
Read by QxMD icon Read
search

American Journal of Hematology

journal
https://www.readbyqxmd.com/read/29790589/genotype-phenotype-correlation-of-hereditary-erythrocytosis-mutations-a-single-center-experience
#1
Jennifer L Oliveira, Lea M Coon, Lori A Frederick, Molly Hein, Kenneth C Swanson, Michelle E Savedra, Tavanna R Porter, Mrinal M Patnaik, Ayalew Tefferi, Animesh Pardanani, Stefan K Grebe, David S Viswanatha, James D Hoyer
Hereditary erythrocytosis is associated with high oxygen affinity hemoglobin variants (HOAs), 2,3-bisphosphoglycerate deficiency and abnormalities in EPOR and the oxygen-sensing pathway proteins PHD, HIF2α, and VHL. Our laboratory has 40 years of experience with hemoglobin disorder testing and we have characterized HOAs using varied protein and molecular techniques including functional assessment by p50 analysis. In addition, we have more recently commenced adding the assessment of clinically relevant regions of the VHL, BPGM, EPOR, EGLN1 (PHD2), and EPAS1 (HIF2A) genes in a more comprehensive hereditary erythrocytosis panel of tests...
May 23, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29790587/prevalence-of-venous-thromboembolism-diagnosed-in-emergency-department-visits-by-cancer-patients-and-associated-healthcare-resource-utilization-in-the-united-states
#2
LETTER
Yu-Wei Chen, Min-Jung Wang, Alok A Khorana
No abstract text is available yet for this article.
May 23, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29770496/long-term-survival-and-loss-in-expectancy-of-life-in-a-population-based-cohort-of-7114-patients-with-diffuse-large-b-cell-lymphoma
#3
Sara Ekberg, Mats Jerkeman, Per-Ola Andersson, Gunilla Enblad, Björn E Wahlin, Sverker Hasselblom, Therese M Andersson, Sandra Eloranta, Karin E Smedby
Survival has improved among patients with diffuse large B-cell lymphoma (DLBCL) with the addition of anti-CD20 antibody therapy. We aimed to quantify trends and remaining loss in expectation of life (LEL) due to DLBCL at a national population-based level. Patients diagnosed with DLBCL 2000-2013 (N=7114) were identified through the Swedish Lymphoma Registry and classified according to the age-adjusted International Prognostic Index (aaIPI).The novel measure LEL is the difference between remaining life years among patients and the general population and was predicted using flexible parametric models from diagnosis and among 2-year survivors, by age and sex...
May 17, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29770480/genetic-biomarkers-of-sensitivity-and-resistance-to-venetoclax-monotherapy-in-patients-with-relapsed-acute-myeloid-leukemia
#4
LETTER
Brenda Chyla, Naval Daver, Kelly Doyle, Evelyn McKeegan, Xin Huang, Vivian Ruvolo, Zixing Wang, Ken Chen, Andrew Souers, Joel Leverson, Jalaja Potluri, Erwin Boghaert, Anahita Bhathena, Marina Konopleva, Relja Popovic
No abstract text is available yet for this article.
May 17, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29770479/impact-of-intranasal-fentanyl-in-nurse-initiated-protocols-for-sickle-cell-vaso-occlusive-pain-episodes-in-a-pediatric-emergency-department
#5
LETTER
Bolanle Akinsola, Robert Hagbom, April Zmitrovich, Patricia L Kavanagh, Ashley Ashkouti, Harold K Simon, Alesia Fleming, Shabnam Jain, Carlton Dampier, Claudia R Morris
No abstract text is available yet for this article.
May 17, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29770476/exceptional-microorganisms-on-blood-smear
#6
Madeleine Rousseaux, Marion Duprilot, Frédérique Maire, Emmanuelle de Raucourt
No abstract text is available yet for this article.
May 17, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29756409/acute-kidney-injury-during-parvovirus-b19-induced-transient-aplastic-crisis-in-sickle-cell-disease
#7
LETTER
Jamie Oakley, Rima Zahr, Inmaculada Aban, Varsha Kulkarni, Rakesh P Patel, Julia Hurwitz, David Askenazi, Jane Hankins, Jeffrey Lebensburger
No abstract text is available yet for this article.
May 14, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29756385/absence-of-early-hhv-6-reactivation-after-cord-blood-allograft-predicts-powerful-graft-versus-tumor-effect
#8
Armin Rashidi, Maryam Ebadi, Bassil Said, Qing Cao, Ryan Shanley, Julie Curtsinger, Nelli Bejanyan, Erica D Warlick, Jaime S Green, Claudio G Brunstein, Jeffrey S Miller, Daniel J Weisdorf
Approximately 75% of cord blood transplant (CBT) recipients experience human herpes virus-6 (HHV-6) reactivation. Considering the immunomodulatory effects of HHV-6, we hypothesized that early HHV-6 reactivation may influence the risk of relapse of the underlying hematologic malignancy. In 152 CBT recipients with hematological malignancies, we determined the association between HHV-6 reactivation by day +28 and 2-year cumulative incidence of relapse. In univariate analysis, the absence of HHV-6 reactivation (n = 32) was associated with less relapse (26 [18-35]% vs...
May 14, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29756344/treatment-with-cyclosporin-in-auto-immune-cytopenias-in-children-the-experience-from-the-french-cohort-obs-cerevance
#9
LETTER
Mathilde Penel Page, Yves Bertrand, Helder Fernandes, Djamel Kherfellah, Guy Leverger, Thierry Leblanc, Clara Libbrecht, Gérard Michel, Eric Jeziorski, Corinne Armari-Alla, Brigitte Nelken, Isabelle Pellier, Marlène Pasquet, Yves Perel, Nathalie Aladjidi
No abstract text is available yet for this article.
May 14, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29756293/spotting-the-elusive-siberian-tiger-complete-response-to-ibrutinib-in-a-patient-with-waldenstr%C3%A3-m-macroglobulinemia
#10
LETTER
Jorge J Castillo, Toni Dubeau, Amanda Kofides, Maria G Demos, Nicholas Tsakmaklis, Lian Xu, Zachary R Hunter, Steven P Treon
No abstract text is available yet for this article.
May 14, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29756251/fixed-low-dose-hydroxyurea-for-the-treatment-of-adults-with-sickle-cell-anemia-in-nigeria
#11
LETTER
Bamidele O Tayo, Titilola S Akingbola, Santosh L Saraf, Binal N Shah, Chinedu A Ezekekwu, Omowunmi Sonubi, Lewis L Hsu, Richard S Cooper, Victor R Gordeuk
No abstract text is available yet for this article.
May 14, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29756305/did-you-miss-me-a-subtle-case-of-intravascular-large-b-cell-lymphoma
#12
Sanjay Patel, Yi Li, Jacob E Berchuck, James Cunningham, Annette Kim, Olga Pozdnyakova
No abstract text is available yet for this article.
May 13, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29756247/fertility-preservation-in-women-with-marrow-failure-syndromes-prior-to-allogeneic-stem-cell-transplantation
#13
LETTER
Alexander R Mehm, David P Steensma, Serene S Srouji, Elizabeth S Ginsburg, Paula C Brady
No abstract text is available yet for this article.
May 13, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29752824/case-series-of-patients-with-severe-sickle-cell-disease-treated-with-voxelotor-gbt440-by-compassionate-access
#14
LETTER
Gershwin Blyden, Kenneth R Bridges, Lanetta Bronte
No abstract text is available yet for this article.
May 12, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29752735/rbpi-21-opebacan-promotes-rapid-trilineage-hematopoietic-recovery-in-a-murine-model-of-high-dose-total-body-irradiation
#15
Kenneth J Janec, Huaiping Yuan, James E Norton, Rowan H Kelner, Christian K Hirt, Rebecca A Betensky, Eva C Guinan
The complexity of providing adequate care after radiation exposure has drawn increasing attention. While most therapeutic development has focused on improving survival at lethal radiation doses, acute hematopoietic syndrome (AHS) occurs at substantially lower exposures. Thus, it is likely that a large proportion of such a radiation-exposed population will manifest AHS of variable degree and that the medical and socioeconomic costs of AHS will accrue. Here, we examined the potential of rBPI21 (opebacan), used without supportive care, to accelerate hematopoietic recovery after radiation where expected survival was substantial (42-75%) at 30 days)...
May 11, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29726580/hla-drb3-4-5-mismatches-are-associated-with-increased-risk-of-acute-gvhd-in-10-10-matched-unrelated-donor-hematopoietic-cell-transplantation
#16
Stéphanie Ducreux, Valérie Dubois, Kahina Amokrane, Ibrahim Yakoub-Agha, Myriam Labalette, Mauricette Michallet, Marie-Thérèse Rubio, Anne Kennel, Edouard Forcade, Xavier Lafarge, Claude-Eric Bulabois, Dominique Masson, Etienne Daguindau, Anne Devys, Virginie Moalic, Erwann Quelvennec, Abdelali Boudifa, Christophe Picard, Peter Van Endert, Muriel de Matteis, Florent Delbos, Matthieu Filloux, Béatrice Pedron, Virginie Renac, Françoise Hau, Julie Bonneau, Anne Parissiadis, Marylise Fort, Anne Dormoy, Natacha Maillard, Isabelle Jollet, Patrice Chevallier, Anne Cesbron, Jacques-Olivier Bay, Fabienne Quainon, Federico Garnier, Gérard Socié, Pascale Loiseau, Raphaël Porcher, Régis Peffault de Latour
Matching for HLA-A, -B, -C, and -DRB1 loci (8/8 match) is currently the gold standard for unrelated donor hematopoietic cell transplantation (HCT). In Europe, patients are also matched at the HLA-DQB1 loci (10/10 match). However, there is increasing evidence that matching at HLA-DRB3/4/5 loci may help to lower transplant-related morbidity and mortality. We therefore investigated the impact of HLA-DRB3/4/5 mismatches on outcomes in 1975 patients who received a first 10/10 matched unrelated donor (MUD) HCT in France from 2000 to 2012 for a hematological malignancy...
May 4, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29726579/nutritional-supplement-profile-of-adults-with-sickle-cell-disease
#17
LETTER
Elena M Crouch, Vence L Bonham, Khadijah Abdallah, Ashley Buscetta, Giacomo Vinces, Moonseong Heo, Caterina P Minniti
No abstract text is available yet for this article.
May 4, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29726031/patient-reported-health-related-quality-of-life-from-the-phase-iii-tourmaline-mm1-study-of-ixazomib-lenalidomide-dexamethasone-versus-placebo-lenalidomide-dexamethasone-in-relapsed-refractory-multiple-myeloma
#18
Xavier Leleu, Tamas Masszi, Nizar J Bahlis, Luisa Viterbo, Bartrum Baker, Peter Gimsing, Vladimir Maisnar, Olga Samoilova, Laura Rosiñol, Christian Langer, Kevin Song, Tohru Izumi, Charles Cleeland, Deborah Berg, Huamao Mark Lin, Yanyan Zhu, Tomas Skacel, Philippe Moreau, Paul G Richardson
TOURMALINE-MM1 is a phase III, randomized, double-blind, placebo-controlled study of ixazomib plus lenalidomide and dexamethasone (IRd) versus placebo-Rd in patients with relapsed/refractory multiple myeloma following 1-3 prior lines of therapy. The study met its primary endpoint, demonstrating significantly longer progression-free survival (PFS) in the IRd arm versus placebo-Rd arm (median 20.6 vs 14.7 months, hazard ratio 0.74, P = 0.01), with limited additional toxicity. Patient-reported health-related quality of life (HRQoL) was a secondary endpoint of TOURMALINE-MM1...
May 4, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29726028/high-vs-low-dose-cyclosporine-a-after-allogeneic-marrow-transplantation-in-leukemia-long-term-follow-up-of-a-randomized-study
#19
LETTER
Andrea Bacigalupo, Maria Teresa Van Lint, Simona Sica, Luca Laurenti, Maria Belen Rosales, Alida Dominietto, Carmen di Grazia, Emanuele Angelucci
No abstract text is available yet for this article.
May 4, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29696694/laboratory-testing-in-bcr-abl1-like-philadelphia-like-b-lymphoblastic-leukemia-lymphoma
#20
Bradford J Siegele, Valentina Nardi
BCR-ABL1-like B-lymphoblastic leukemia/lymphoma (BCR-ABL1-like B-ALL), also known as Philadelphia-like (Ph-like) ALL, is a neoplasm of B-lineage lymphoblasts characterized by a pattern of gene expression similar to that of B-ALL with the BCR-ABL1 translocation but lacking the BCR-ABL1 fusion protein with a high rate of relapse and poor outcome. In recognition of the difficulty in screening these leukemias for diagnostic workup, and of the complexity of the workup itself, the 2016 update/revision to the World Health Organization (WHO) 2008 edition included BCR-ABL1-like B-ALL as a provisional entity...
April 26, 2018: American Journal of Hematology
journal
journal
26814
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"